Express Mail Label No.: EV058074656US

Date of Deposit: March 25, 2002



Attorney Docket NOTER 1800/26

OFFICE

OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Karen M. Lyons

SERIAL NO.:

10/005,228

FILING DATE:

December 3, 2001

For:

Method and Composition for Modulating Bone Growth

Box IDS

Commissioner for Patents Washington, D.C. 20231

Reference No. 22058-554.

INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Information Disclosure Statement is being been filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311

Respectfully submitted

Lyof R. Elriff/(Reg. No. 39,529)/ David E. Johnson (Reg. No. 41,874)

Attorneys for Applycants

c/o MINTZ, LEVIN, COHN, FERRIS GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: March 25, 2002

TRA 1639963v1

Express Mail No. EV058074656US Date of Deposit: March 25, 2002

Please type a plus sign (+) in this box





Modified Form 1449/PTO	Application Number	10/005,228	- 30	ď
	Filing Date	December 3, 2001	<u> </u>	N2
INFORMATION DISCLOSURE `	First Named Inventor	Lyons	-0/2	70
STATEMENT BY APPLICANT	Group Art Unit	1636	- 99	
	Examiner Name	Not Yet Assigned	.0	
(use as many sheets as necessary)	Attorney Docket Number	22058-554		

U.S. PATENT DOCUMENTS							
Exam Cite No.		U.S. Patent Document No.	Issue Date Name of Patentee(s) or Applicant(s)		Class	Sub Class	Filing Date If Appropriate
	A1	5,116,738	05/26/92	Wang, et al.			
A2 5,688,678 11/18/97		Hewick, et al.					
	A3	6,287,816	09/11/01	Rosen, et al.			

FOREIGN PATENT DOCUMENTS								
Exam Cit Initials No				Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	wo	88/00205	Genetics Institute, Inc.	01/14/1988			
	B2	wo	89/10409	Genetics Institute, Inc.	11/02/1989			
	В3	wo	90/11366	Genetics Institute, Inc.	10/04/1990			
	B4	wo	99/53049	Abgenix, Inc.	10/21/1999			

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS								
Exam Initials	Cite No.							
r	C1	Brodeur, et al. (1987). "Mouse-Human Myeloma Partners for the Production of Heterohybridomas." <i>Monclonal Antibody Production Techniques and Applications</i> : 51-63. (Marcel Dekker, Inc.).						
	C2	Huse, et al. (1989). "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda." Science 246: 1275-1281.						
	C3	Lonberg, et al. (1994). "Antigen-specific human antibodies from mice compromising four distinct genetic modifications." <i>Nature</i> 368: 856-859.						
	C4	Shopes (1992). "A Genetically Engineered Human IgG Mutant with Enhanced Cytolytic Activity." <i>J. immunol.</i> 148(9): 2918-2922.						
	C5	Tutt, et al. (1991). "Trispecific F(ab')3 Derivatives that Use Cooperative Signaling Via TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells. <i>J. immunol.</i> 147: 60-69.						
	C6	Thies, et al. (1992). "Recombinat Human Bone Morphogenetic Protein-2 Induces Osteoblastic Differentiation in W-20-17 Stromal Cells." <i>Endocrinol.</i> 130: 1318-1324.						
C8 Bo		Engstrad, et al. (2000). "Transient Production of Bone Morphogenetic Protein 2 by Allogeneic Transplanted Transduced Cells Induces Bone Formation." <i>Hum. Gene Ther.</i> 11: 205-211.						
		Bostrom, et al. (1993). "Immunolocalization and Expression of Bone Morphogenetic Proteins 2 and 4 in Fract Healing." <i>J. Orthop. Res.</i> <u>13</u> : 357-367.						
	C9	Wozney, et al. (1993). "Bone Morphogenetic Proteins." <u>Physiology and Pharmacology of Bone</u> . Pages 725-748. (Edited by Martins and Mundy).						
	C10	Harland (1994). "The transforming growth factor β family and induction of the vertebrate mesoderm: Bone morphogenetic proteins are ventral inducers." <i>Proc. Natl. Acad. Sci. USA</i> <u>91</u> : 10243-10246.						
	C11	Hollnagel, et al. (1999). "Id Genes Are Direct Targets of Bone Morphogenetic Protein Induction in Embryonic Stem Cells." <i>J. Biol. Chem.</i> 274: 19838-19845.						
	C12	Katagiri, et al. (1994). "Bone Morphogenetic Protein-2 Converts the Differentiation Pathway of C2C12 Myoblasts into the Osteoblast Lineage." <i>J. Cell Biol.</i> 127(6): 1755-1766.						

Exp	ress	Mail	No.	E۷	058	07	465	6 U	ıs

Date of Deposit: March 25, 2002



Page 2 of 2

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication Volume, Page(s), Date, Etc.				
	C13	Liu, et al. (1995). "Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes." A the developing skull." <i>Proc. Natl. Acad. Sci. USA</i> 92: 6137-6141.				
	C14	Brummel, et al. (1994). "Characterization and Relationship of Dpp Receptors Encoded by the saxophone thick veins Genes in Drosophila." <i>Cell</i> 78: 251-261.				
	C15	Penton, et al. (1994). "Identification of Two Bone Morphogenetic Protein Type I Receptors in Drosophila and Evidence That BrkCell 78: 239-250.				
	C16	Hoodless, et al. (1996). "MADR1, a MAD-Related Protein that Functions in BMP2 Signaling Pathways." <i>Cell</i> <u>85</u> : 489-500.				
	C17	Attisano, et al. (1993). "Identification of Human Activin and TGF type I Receptors That Form Heteromeric Kinase Complexes with Type II Receptors." <i>Cell</i> 75: 671-680.				
	C18	Macias-Silva, et al. (1998). "Specific Activation of Smad1 signaling Pathways by the BMP7 Type I Receptor, ALK2." J. Biol. Chem. 273(40): 25628-25636.				
	C19	GenBank Accession Number: NM_000020 (12/01/2000).				
	C20 GenBank Accession Number: XM_042360 (10/16/2001).					
Serial No	o	reference is not provided as it was previously cited by or submitted to the office in a prior application,				
Examin	er	Date				

į	(continuation,	continuation-in-part, and divisional applications).		
	Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1634481v1